Aderis Pharmaceuticals


Aderis Pharmaceuticals

Hopkinton, Mass.
Founded: 1994

Why It's Fierce: Effective treatments for central nervous system disorders remain few and far between. We think Aderis has a few winners in its portfolio. The company tailors small molecule to regulate dopamine and other proteins. Aderis has four products in Phase II or Phase III studies including a transdermal patch for Parkinson's disease and a treatment for restless legs syndrome. We're not the only ones betting on Aderis. Germany's Schwarz Pharma, King Pharmaceuticals, and Fujisawa Healthcare have pledged capital and marketing support for the company's lead products.

What to look for in 2003: Look for results from a pivotal study in Parkinson's disease this year.

Aderis Pharmaceuticals

Suggested Articles

Researchers are studying the retrovirus KoRV-A, which is spreading among koalas, to gain new insights into how DNA evolves.

Shionogi and Hsiri Therapeutics first joined forces last year in a licensing and R&D deal focused on tuberculosis and non-tuberculous lung infections.

The efficacy results suggest the experimental oral therapy, abrocitinib, has a shot at challenging the blockbuster biologic incumbent.